Galcanezumab
- Generic Name
- Galcanezumab
- Brand Names
- Emgality
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1578199-75-3
- Unique Ingredient Identifier
- 55KHL3P693
- Background
Galcanezumab is a humanized monoclonal antibody developed by Eli Lilly and Company against human calcitonin gene-related peptide (CGRP). Although several small-molecule CGRP receptor antagonists have been developed, humanized monoclonal antibodies like galcanezumab are specifically designed to selectively bind to CGRP entities with high potency. Given this t...
- Indication
Galcanezumab is indicated in adults for the preventive treatment of migraine and the treatment of episodic cluster headache.
- Associated Conditions
- Episodic Cluster Headache, Migraine
- Associated Therapies
- -
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Allergan
- Target Recruit Count
- 40
- Registration Number
- NCT04179474
- Locations
- 🇺🇸
Spaulding, West Bend, Wisconsin, United States
🇺🇸QPS, Springfield, Missouri, United States
Anti-CGRP for Inflamation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia
- Conditions
- Interventions
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Duke University
- Target Recruit Count
- 20
- Registration Number
- NCT04158752
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT04085289
- Locations
- 🇨🇳
HuaShan Hospital Affiliated To Fudan University, Shanghai, Shanghai, China
A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine
- First Posted Date
- 2019-05-24
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 520
- Registration Number
- NCT03963232
- Locations
- 🇨🇳
First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
🇮🇳All India Institute of Medical Sciences, New Delhi, Delhi, India
🇮🇳Sir Ganga Ram Hospital, New Delhi, Delhi, India
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 463
- Registration Number
- NCT03559257
- Locations
- 🇬🇧
Kings College Hospital, London, Greater London, United Kingdom
🇺🇸Health Research of Hampton Roads Inc, Newport News, Virginia, United States
🇨🇿Clintrial, s.r.o., Praha 10, Hl. M. Praha, Czechia
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 325
- Registration Number
- NCT03432286
- Locations
- 🇺🇸
Premiere Research Institute at Palm Beach Neurology, West Palm Beach, Florida, United States
🇺🇸Clinical Integrative Research Center of Atlanta, LLC, Atlanta, Georgia, United States
🇺🇸Rare Disease Research, LLC, Atlanta, Georgia, United States
A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 311
- Registration Number
- NCT02959190
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yamaguchi, Japan
🇯🇵For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Ōsaka, Japan
A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 459
- Registration Number
- NCT02959177
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yamanashi, Japan
🇯🇵For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Nishinomiya, Japan
🇯🇵"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Nishinomiya, Japan
A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache
- Conditions
- Interventions
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 165
- Registration Number
- NCT02797951
- Locations
- 🇺🇸
California Medical Clinic for Headache, Santa Monica, California, United States
🇺🇸Atlanta Center of Medical Research, Atlanta, Georgia, United States
🇨🇦Stroyan Research, Toronto, Ontario, Canada
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1117
- Registration Number
- NCT02614261
- Locations
- 🇺🇸
Pharmacology Research Institute, Newport Beach, Newport Beach, California, United States
🇺🇸Boston Clinical Trials Inc, Boston, Massachusetts, United States
🇺🇸Artemis Institute for Clinical Research, San Diego, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.